Early Mitral Valve Repair to Help Reach Full Heart Failure Medication Doses
Tests early mitral valve repair in adults with weak-pumping heart failure and leaky valve.
Plain-language title generated from the registry record
Registry title: Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
Key facts
- Where
- Mainz, GermanySee the site
Where in Germany
- Universitätsmedizin MainzMainz, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Mainz
- Trial code
- NCT07758023
- Record updated
- 2 November 2026
- Original description
The purpose of the ACHILLES-HF trial (ACHIeving optimaL medicaL therapy through pErcutaneous treatment of Secondary mitral regurgitation to improve outcome in Patients with Heart Failure with reduced ejection fraction) is to test whether early transcatheter edge-to-edge repair (TEER) in patients with heart failure and reduced ejection fraction (HFrEF) and relevant secondary mitral regurgitation, that are at risk of not receiving full guideline recommended therapy (GDMT), results in faster and more complete GDMT up-titration and whether this translates into improved quality of life and clinical outcomes.Read full original descriptionShow less
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
The purpose of the ACHILLES-HF trial (ACHIeving optimaL medicaL therapy through pErcutaneous treatment of Secondary mitral regurgitation to improve outcome in Patients with Heart Failure with reduced ejection fraction) is to test whether early transcatheter edge-to-edge repair (TEER) in patients with heart failure and reduced ejection fraction (HFrEF) and relevant secondary mitral regurgitation, that are at risk of not receiving full guideline recommended therapy (GDMT), results in faster and more complete GDMT up-titration and whether this translates into improved quality of life and clinical outcomes.
Inclusion: Heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction ≤40%); Clinically significant functional mitral regurgitation (moderate-to severe or severe MR) as defined by European Association of Echocardiography, within 90 days prior to randomization (i.e. EROA ≥0.2 cm² and/or regurgitant fraction >30%); Suboptimal GDMT therapy corresponding to a GDMT score <7 points; Risk factor for not intensification of guideline directed medical therapy (at least one of the following):; Office systolic blood pressure <120 mmHG; Chronic renal failure with eGFR <60 ml/min/1.73m; History of acute kidney injury (AKI) at least stage 2 within the last 12 months; Serum Potassium ≥ 4.8 mmol/L; Persisting symptoms equalling NYHA functional class II-IVa (ambulatory); Patient has had at least one HF hospitalization within 12 months and/or a NT-proBNP ≥1000 pg/ml; Interventional cardiologist believes secondary MR can be successfully treated by an interventional approach; The subject has been informed of the nature of the study and agrees to the study's provisions, including the possibility of randomization to the Control group, and has provided written informed consent as approved by the respective clinical site's Ethics Committee.
Exclusion: Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the investigator; Currently participating in another investigational therapeutic or interventional clinical trial, or in any trial of an unapproved drug, device or procedure. Note: Subjects participating in observational studies or registries may be considered as eligible; Terminal heart failure or hemodynamic instability; Primary TR or MR, any other severe valvular heart disease; Untreated clinically significant CAD (coronary artery disease) requiring revascularization; Renal failure requiring dialysis; Life expectancy <12 months due to non-cardiac conditions; Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated); Active infections requiring current antibiotic therapy; Known hypersensitivity or contraindication to procedural device which cannot be adequately managed medically; LVEF <35% and left bundle branch block with a QRS duration >150 ms; Mitral valve orifice area <4.0 cm² by site assessed TTE; KCCQ score > 80 points; Patient is pregnant, nursing, or planning to be pregnant; Ineligibility to consent.